HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies
Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.
You may also be interested in...
Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.
Targeted Importation: A Drug Pricing Mechanism For 'Predatory Actors' And An A-Pauling HHS Confirmation Dilemma
For those old drug re-pricing situations that reach headline and/or US congressional visibility, a tweak to the importation debate might offer a response.
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.